TARGET AUDIENCE:
Medical oncologists, radiation oncologists, thoracic surgeons and other allied healthcare professionals.

GLOBAL LEARNING OBJECTIVES:
Upon completion of this activity, participants should be able to:

• Develop an evidence-based algorithm for the referral of appropriate patients with localized non-small cell lung cancer (NSCLC) for participation in clinical trials examining the utility of biologic therapy in combination with standard neoadjuvant and adjuvant systemic therapy.
• Create optimal protocol and nonprotocol management strategies for patients with locally advanced Stage III NSCLC, incorporating the concepts of induction chemotherapy, concomitant chemoradiation therapy and the role of consolidation regimens.
• Employ multiple sequential treatment approaches for patients with de novo or recurrent advanced NSCLC, based on an understanding of:
  - The benefits and risks of combination and single-agent chemotherapy regimens.
  - The relevance and impact of advanced age and compromised PS on selection of therapy.
  - The current data on EGFR- and/or VEGF-inhibiting agents.
• Utilize currently available biologic and clinical markers to predict response to targeted therapy.
• Select appropriate prophylactic and/or acute clinical management approaches for patients experiencing toxicities associated with VEGF, EGFR and multikinase inhibitors.

CME EVALUATION:
An evaluation form will be given to each participant at the conclusion of this activity.

ACCREDITATION STATEMENT:
Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

CREDIT DESIGNATION STATEMENT:
Research To Practice designates this educational activity for a maximum of 2.5 AMA PRA Category 1 Credit(s)™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

DISCLOSURE POLICY:
As a provider accredited by the Accreditation Council for Continuing Medical Education, it is the policy of Research To Practice to require the disclosure of any significant financial interest or any other relationship the sponsor or faculty members have with the manufacturer(s) of any commercial product(s) discussed in an educational presentation. Financial disclosures and disclosures of discussions of unlabeled/unapproved uses of drugs or devices will be provided in meeting course materials.